A compound comprising the structure of Formula II(b) for use in the treatment of an inflammatory disease: or a pharmaceutically acceptable salt, or solvate thereof, wherein, R 11 is =O or is absent; R 15 is selected from the group consisting, an optionally substituted heterocycle, an optionally substituted aryl, an optionally substituted benzyl, and an optionally substituted (C 3 -C 8)cycloalkyl, -CH 2 (R 19), -CH(R 19) 2, -NH(R 19) and -N(R 19) 2; R 16 and R 17 are independently selected from the group consisting of H, halo, hydroxyl, cyano, nitro, ester, alkoxy, amino, thiol, sulfinyl, sulfonyl, sulfino, sulfo, thiocyanato, isothiocyanato, thial, borono, boronate, phosphate, aldehyde, carboxyl, carboxamido, azido, cyanato, isocyanato, an optionally substituted (C 1 -C 6)alkyl, an optionally substituted(C 2 -C 6)alkenyl, an optionally substituted (C 2 -C 6)alkynyl, an optionally substituted (C 1 -C 6)hetero-alkyl, an optionally substituted (C 2 -C 6)hetero-alkenyl, an optionally substituted (C 2 -C 6)hetero-alkynyl, an optionally substituted (C 3 -C 8)cycloalkyl, an optionally substituted aryl, and an optionally substituted heterocycle; R 18 is selected from the group consisting of -CH 2 (R 19), -CH(R 19) 2, -NH(R 19), -N(R 19) 2, an optionally substituted heterocycle, an optionally substituted aryl, an optionally substituted benzyl, and an optionally substituted (C 3 -C 8)cycloalkyl; and R 19 is selected from the group consisting of an optionally substituted (C 3 -C 16) alkyl, an optionally substituted(C 3 -C 16)alkenyl, an optionally substituted (C 3 -C 16)alkynyl, an optionally substituted (C 3 -C 15)hetero-alkyl, an optionally substituted (C 3 -C 15)hetero-alkenyl, an optionally substituted (C 3 -C 15)hetero-alkynyl, an optionally substituted heterocycle, an optionally substituted aryl, an optionally substituted benzyl, and an optionally substituted (C 3 -C 8)cycloalkyl, and wherein the inflammatory disease is selected from colitis, asthma, inflammatory bowel disease, Crohn's disease, ulcerative colitis, Alzheimer's disease, and Nakajo-Nishimura syndrome. R 11 is =O or is absent; R 15 is selected from the group consisting, an optionally substituted heterocycle, an optionally substituted aryl, an optionally substituted benzyl, and an optionally substituted (C 3 -C 8)cycloalkyl, -CH 2 (R 19), -CH(R 19) 2, -NH(R 19) and -N(R 19) 2; R 16 and R 17 are independently selected from the group consisting of H, halo, hydroxyl, cyano, nitro, ester, alkoxy, amino, thiol, sulfinyl, sulfonyl, sulfino, sulfo, thiocyanato, isothiocyanato, thial, borono, boronate, phosphate, aldehyde, carboxyl, carboxamido, azido, cyanato, isocyanato, an optionally substituted (C 1 -C 6)alkyl, an optionally substituted(C 2 -C 6)alkenyl, an optionally substituted (C 2 -C 6)alkynyl, an optionally substituted (C 1 -C 6)hetero-alkyl, an optionally substituted (C 2 -C 6)hetero-alkenyl, an optionally substituted (C 2 -C 6)hetero-alkynyl, an optionally substituted (C 3 -C 8)cycloalkyl, an optionally substituted aryl, and an optionally substituted heterocycle; R 18 is selected from the group consisting of -CH 2 (R 19), -CH(R 19) 2, -NH(R 19), -N(R 19) 2, an optionally substituted heterocycle, an optionally substituted aryl, an optionally substituted benzyl, and an optionally substituted (C 3 -C 8)cycloalkyl; and R 19 is selected from the group consisting of an optionally substituted (C 3 -C 16) alkyl, an optionally substituted(C 3 -C 16)alkenyl, an optionally substituted (C 3 -C 16)alkynyl, an optionally substituted (C 3 -C 15)hetero-alkyl, an optionally substituted (C 3 -C 15)hetero-alkenyl, an optionally substituted (C 3 -C 15)hetero-alkynyl, an optionally substituted heterocycle, an optionally substituted aryl, an optionally substituted benzyl, and an optionally substituted (C 3 -C 8)cycloalkyl, and wherein the inflammatory disease is selected from colitis, asthma, inflammatory bowel disease, Crohn's disease, ulcerative colitis, Alzheimer's disease, and Nakajo-Nishimura syndrome.